Chemomab Therapeutics (CMMB) Debt Ratio (2018 - 2019)
Chemomab Therapeutics' (CMMB) quarterly Debt Ratio came in at 0.3 in Q3 2019, up 390.7% quarter-over-quarter from 0.06 in Q2 2019.
Powered by 
Analysis
Chemomab Therapeutics (CMMB) Debt Ratio (2018 - 2019) Analysis & Trends
Chemomab Therapeutics (CMMB) has reported Debt Ratio for 2 consecutive years, with 0.3 the latest figure, recorded in Q3 2019.
- For the quarter ending Q3 2019, Debt Ratio changed N/A year-over-year to 0.3; the trailing twelve-month figure through Sep 2019 stood at 0.3 (changed N/A YoY), and the FY2018 full-year result was 0.55, changed N/A from the prior year.
- Debt Ratio improved to 0.3 in Q3 2019 per CMMB's latest filing, from 0.06 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.55 in Q4 2018 and bottomed at 0.06 in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 0.66 |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 0.05 |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 0.05 |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 0.25 |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 0.26 |
| 10 | Chemomab Therapeutics | 19.49 Mn | 19.49 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2019 | 0.30 |
| Jun 30, 2019 | 0.06 |
| Dec 31, 2018 | 0.55 |